drugset / Trial / NCT03427476
CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma
Phase 1
Completed
4 enrolled
Cancer Targeted Technology
University of California, San Francisco · collab
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
The purpose of this study is to test a novel diagnostic PET imaging agent for safety and biodistribution. The agent binds PSMA and is designed to detect Prostate Specific Membrane Antigen expressing tumors, such as has been described for some renal cell carcinoma tumors.
Timeline
- Start
- 2018-01-01
- Primary completion
- 2018-08-31
- Completion
- 2018-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CTT1057 | Small molecule | 20 ug | Intravenous |
| Subject | CTT1057 | Small molecule | 370 mbq | Intravenous |